Article Under Review
Article Under Review
Therapeutic Drug Monitoring Market worth $2.9 billion by 2027
Therapeutic Drug Monitoring Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by the Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis. However, Alternatives to conventional TDM may challenge the growth of this market.
Attractive Opportunities in the Therapeutic Drug Monitoring Industry
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443
Browse in-depth TOC on "Antiepileptic Drug Monitoring Industry"
178 - Tables
50 - Figures
221 – Pages
Germany in European Antibiotic Therapeutic drug monitoring market to witness the highest shares during the forecast period.
The Europe Therapeutic Drug Monitoring Market is segmented into Germany, Italy, France, Spain, the UK, and the Rest of Europe. Germany is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the rising geriatric population, increasing incidence of chronic and infectious diseases, rising healthcare expenditure, and increasing R&D investments.
Japan dominates the Asia Pacific Immunosuppressant Drug Monitoring industry
The APAC Therapeutic Drug Monitoring market is segmented into Japan, China, and India. In 2021, Japan accounted for the largest share of the Asian Therapeutic Drug Monitoring market. The large share of Japan can be attributed to the large geriatric population in the country, the rising prevalence of chronic medical conditions such as cancer, growing budgetary allocations for healthcare, and the presence of a well-developed healthcare system.
chemiluminescence immunoassays (CLIAs) in the product's immunoassay therapeutic drug monitoring segment to witness the highest growth as well as the largest share in the therapeutic drug monitoring market during the forecast period.
The market is divided into chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, and other immunoassays based on the immunoassay. The chemiluminescence immunoassays segment is projected to grow at the highest CAGR during the forecast period because these assays are commonly used in TDM in either enzyme-amplified or direct chemiluminescence measurements.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=155350443
Antiarrhythmic Drug Monitoring Industry Dynamics:
Drivers:
- Importance of TDM in organ transplant procedures
- Use of TDM across various therapeutic fields
- Increasing preference for precision medicine
- Growing focus on R&D related to TDM
- Technological advancements
Restraints:
- Requirement of high capital investments
- Reluctance of small hospitals to offer TDM services
Opportunities:
- Increasing adoption in the treatment of autoimmune diseases
Challenges:
- Alternatives to conventional TDM
- Operational barriers faced in conducting TDM
Key Market Players:
The significant players in the Therapeutic Drug Monitoring industry are Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ARK Diagnostics, Inc. (US), apDia Group (Belgium), Immundiagnostik AG (Germany), and Sekisui Medical Co. Ltd. (Japan).
Recent Developments:
- In May 22, Theradiag (France) Announced the launch of ez-Track1, a Point-of-Care Testing solution for TDM.
- In Jan 2021, Theradiag (France) Announced CE marking for four new i-Tracker test kits for biotherapy monitoring.
Report Objectives
- To define, describe, and forecast the global Therapeutic Drug Monitoring market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Therapeutic Drug Monitoring market
Frequently Asked Questions (FAQ):
What is the projected market value of the global Therapeutic Drug Monitoring Market?
The global market of Therapeutic Drug Monitoring is projected to reach USD 2.9 billion by 2027.
What is the estimated growth rate (CAGR) of the global Therapeutic Drug Monitoring Market for the next five years?
The global Therapeutic Drug Monitoring market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.6% from 2022 to 2027.
Who are the major players offering Therapeutic Drug Monitoring in the market?
Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany)
Who are the significant end users in Therapeutic Drug Monitoring Market?
Hospital laboratories, commercial & private laboratories, are the major end users in Therapeutic Drug Monitoring Market.
Which Immunoassay will have the highest shares in Therapeutic Drug Monitoring Market during the forecast period?
Chemiluminescence Immunoassays will have the highest shares of the Therapeutic Drug Monitoring market during the forecast period
Report Link: ( Therapeutic Drug Monitoring Market )
About MarketsandMarkets™
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/therapeutic-drug-monitoring-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/therapeutic-drug-monitoring.asp
Related Report:
Precision Medicine Market: The report "Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) - Global Forecast to 2028 ", is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period.
Rehabilitation Equipment Market worth $19.8 billion by 2027
The Global Rehabilitation Equipment Market is projected to reach USD 19.8 billion by 2027 from USD 14.9 billion in 2022, at a CAGR of 5.9% during the forecast period. The growth of this market is primarily driven by the increasing prevalence of chronic diseases such as arthritis and cancer, requiring rehabilitation therapies, high risk of injuries to caregivers during the manual handling of patients, rising geriatric and obese populations, and increasing demand for rehabilitation therapies owing to increasing access to healthcare. However, reimbursement issues and persistent difficulties in handling bariatric patients are some of the key challenges in the market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194775519
Mobility Equipment Market Dynamics
Drivers:
The manual handling of disabled patients may result in severe musculoskeletal injuries to caregivers. The risk of back injuries increases during lateral transfer, as caregivers must reach over the stretcher to the bed and physically pull the patient across onto a stretcher. This movement forces the body of caregivers into an awkward posture, which can cause musculoskeletal discomfort.
Restraints: Lack of awareness and access to rehabilitation services in emerging markets
A general lack of awareness on the effective use of rehabilitation equipment is expected to restrain the growth of this market. For example, in the case of a stroke, the lack of proper assistance and rehabilitation at the correct juncture can have significant ill-effects on the functioning of the body. This lack of awareness can also lead to patients neglecting the symptoms of critical conditions entirely, which affects the adoption of rehabilitation. This is a key problem in countries, such as Malaysia and Taiwan, where the effects of this factor are compounded by a lack of sufficient infrastructure and manpower.
Opportunities: Rising demand for home healthcare services
Globally, an increasing number of government regulations are being implemented to reduce the duration and cost involved in healthcare treatments. The provision of services at a patient’s home is typically more cost-effective than in institutions, particularly if the available informal care is used effectively. Moreover, with the evolution of new technologies, such as remote patient monitoring, the home care segment is expected to witness significant growth in the coming years. The growing demand for home care will, in turn, increase the demand for equipment required for treating patients in home care settings, including patient transfer devices, mobility devices, and medical beds, in the coming years
Challenges: Reimbursement issues
Reimbursement is a key area that directly affects the adoption of rehabilitation equipment. A number of products in this market are priced at a premium and may not be affordable for patients; in such a case, they would have to depend on reimbursement to access the equipment. Various organizations, such as Medicare and Medicaid in the US, provide only limited coverage for rehabilitation equipment such as hospital beds, patient lifts, commode chairs, crutches, walkers, and manual and electric wheelchairs and scooters. Moreover, this coverage is only applicable for the purchase or rentals from Medicare suppliers, as the supplier is prohibited by Medicare rules to charge more than the Medicare-approved amount for equipment.
“The rehabilitation equipment industry is projected to grow at a CAGR of 5.9% between 2022 and 2027.”
The global market is projected to reach USD 19.8 billion by 2027 from USD 14.9 billion in 2022, at a CAGR of 5.9% during the forecast period. The growth of this market is primarily driven by significant risk of injuries to caregivers while manually handling the patients, increasing growth in geriatric and obese population that often requires rehabilitation therapies, and an increasing demand for rehabilitation care with an increasing access to healthcare. However, a lack of training provided to caregivers for the efficient operation of rehabilitation equipment is a major factor restraining market growth.
“Therapy equipment was the largest and fastest-growing segment by product”
Based on product, the rehabilitation equipment market is segmented into therapy equipment, daily living aids, mobility equipment, exercise equipment, and body support devices. In 2021, the therapy equipment segment accounted for the largest share of the global market. Increasing growth in the patients opting for physiotherapy and rehabilitation therapies are driving the demand for therapy equipment globally.
“physical rehabilitation & training segment is the largest application segment”
Based on application, the rehabilitation equipment market is segmented into strength, endurance, and pain reduction; physical rehabilitation & training; and occupational rehabilitation & training. In 2021, the physical rehabilitation & training segment accounted for the largest share of the global market. Physical rehabilitation and training help with osteoarthritis, joint replacement, sports injury, knee pain, back pain, carpal tunnel syndrome, Alzheimer's disease, multiple sclerosis, and cerebral palsy. Increasing incidence of above mentioned injuries and diseases are resulting into a significant growth in the segment.
“Hospitals and clinics segment is the largest end user segment”
Based on end users, the rehabilitation equipment market is segmented into hospitals & clinics, rehabilitation centers, physiotherapy centers, home care settings, and other end users. In 2021, the hospitals and clinics segment accounted for the largest share of the global market. Medical beds, slings, hoists, and bathroom and toilet assist devices are commonly used rehabilitation equipment across hospitals. The demand for these equipment are increasing owing to increasing prevalence of diseases/conditions requiring hospital-based treatment.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=194775519
“Europe to witness the highest growth rate during the forecast period.”
Europe accounted for the largest share of the global rehabilitation equipment market. The large share of this regional segment is attributed to a significant contribution from an economically stable and technologically advanced countries such as Germany, UK, and France. Increasing geriatric population and rising prevalence of musculoskeletal disorders across these countries are driving the market growth in Europe. The Asia Pacific market is projected to register the highest CAGR during the forecast period. Market growth in the Asia Pacific is attributed to the rising healthcare expenditure and growing number of healthcare facilities in Asian countries.
Recent Developments
- In May 2022, Etac AB (Sweden) announced the launch of R82 Crocodile (size 0), the smallest walking aid by the company.
- In March 2022, Medline Industries, LP (US) announced a USD 725 million prime vendor partnership with Mount Sinai Health System (US), to enhance their supply chain strategy and improve patient outcomes.
- In March 2022, Prism Medical (UK) announced a partnership with IoT Solution Group (UK), to enable Prism Medical to advance its existing product portfolio and expand into the smart healthcare market.
- In February 2022, Invacare announced the launch of its next-generation e-fix eco Power Assist Device to upgrade its manual wheelchairs.
Key Market Players:
Baxter International (US), Invacare Corporation (US), Medline Industries, LP (US), Arjo (Sweden), Colfax Corp. (US), Dynatronics Corp. (US), Handicare Group AB (Sweden), Drive DeVilbiss International (Germany), Etac AB (Sweden), GF Health Products Inc. (US), Joerns Healthcare LLC (US), Prism Medical UK Ltd. (UK), Guldmann (Denmark)
Objectives of the Study
- To define, describe, and forecast the rehabilitation equipment market on the basis of product, application, end user, and region
- To provide detailed information about the factors influencing the market growth (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets1 with respect to the individual growth trends, prospects, and contributions to the overall rehabilitation equipment market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and rest of the world.
- To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and recent financials
- To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the rehabilitation equipment market
Regenerative Medicine Market worth $49.0 billion by 2028
The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $16.0 Billion in 2023 and is poised to reach $49.0 Billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. This is mainly due to various factors such as rising emphasis on personalized medicine, rising partnerships and collaborations by major market players, increased therapeutic area scope and rise in regenerative medicine regulatory approvals. However, the legal and ethical concerns associated with regenerative medicine along with the growing high treatment cost are predicted to cause market growth barriers.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579
Browse in-depth TOC on "Regenerative Medicine Market"
258 - Tables
48 - Figures
303 – Pages
The regenerative medicine market is predicted to grow at a CAGR of 25.1% during the forecast period of 2023 to 2028. The important factors impacting market growth are the increasing focus on personalized medicine, and the emerging applications in new therapeutic areas. Increasing collaborations and partnerships by major market players and increasing regulatory approvals in regenerative medicine are expected to provide lucrative growth of the market in the near future.
Cell therapy segment accounted for the largest share of the regenerative medicine market
Based on product, the regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {Autologous stem cell therapy, allogenic stem cell therapy] cell-based immunotherapy products), and tissue engineering products. The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022. The high adoption of stem cell therapy is a key contributor to the growth of this segment. The growing applications of hematopoietic stem cell transplantations (HSCT) are expected to drive the growth of the cell therapy market.
Musculoskeletal disorder wins the largest share of therapeutic areas
Based on therapeutic area, the regenerative medicine market is classified into oncology, neurology, musculoskeletal disorders, ophthalmology, cardiovascular diseases, dermatology & wound care and other applications. In 2022, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market. Rise in the orthopedic disorders prevalence along with increasing musculoskeletal regeneration research can be attributed to the rising growth rate of this segment.
During the forecast period, North America exhibited the most rapid growth.
The largest share of the global regenerative medicine market was of North America, closely followed by Europe and then the Asia Pacific. This can be accredited to the growth of stem cell research, healthcare sector expansion, and the increase in the adoption of stem cell therapy and cell immunotherapies for cancer and other chronic diseases treatment.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579
Key Market Players:
Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CORESTEM, Inc (South Korea), Vericel Corporation (US), MIMEDX Group, Inc. (US), Organogenesis Inc. (US), Medtronic (Ireland), Bristol-Myers Squibb Company (US), Orthocell Ltd. (Australia), Mesoblast Ltd. (Australia), BioRestorative Therapies, Inc. (US), Pluristem Therapeutics Inc. (US), TEGOSCIENCE (South Korea), ANTEROGEN.CO.,LTD. (South Korea), Bluebird bio, Inc. (US), Stempeutics Research Pvt Ltd. (India), Sibiono GeneTech Co. Ltd. (China), Aspect Biosystems Ltd. (Canada), and Athersys, Inc. (US).
Market Dynamics
Drivers
- Growing focus on personalized medicine
- Emerging applications in new therapeutic areas
- Increasing collaborations and partnerships by major market players
- Increasing regulatory approvals in regenerative medicine
Restraints
- Lack of long-term data
- Ethical and legal concerns and high cost of treatments
Opportunities
- Harnessing the potential of 3D printing
- Integration with artificial intelligence and big data
- Growing number of organ transplants
Challenges
- Lack of favorable reimbursement policies across various regions
Recent Developments of Regenerative Medicine Industry:
- In December 2023, the U.S. FDA greenlit a historic treatment, Casgevy (CRISPR Therapeutics.). This first-ever cell-based gene therapy tackled sickle cell disease in patients 12+ and marked a revolutionary step in gene therapy with its novel genome editing tech.
- In January 2023, Sarepta and Catalent entered into a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001) (ELEVIDYS), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD).
- In August 2023, Gilead Sciences and Tentarix Biotherapeutics entered into three multi-year collaborations to leverage Tentarix's Tentacles platform for the discovery and development of innovative, multi-functional protein-based therapies for cancer and inflammatory diseases.
- In December 2023, Bristol-Myers Squibb received approval for ABECMA for patients with relapsed or refractory multiple myeloma with at least two prior treatments, including specific medications in Japan.
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/regenerative-medicine-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/regenerative-medicine.asp
Related Links:
https://finance.yahoo.com/news/regenerative-medicine-market-expected-reach-123000076.html
Healthcare Simulation Market Size, Share, Trends and Revenue Forecast [2028]
Healthcare Simulation Market in terms of revenue was estimated to be worth $2.3 billion in 2023 and is poised to reach $5.2 billion by 2028, growing at a CAGR of 15.7% from 2023 to 2028 according to a new report by MarketsandMarkets™.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1156
Browse in-depth TOC on "Healthcare Simulation Market"
217 - Tables
41 - Figures
305 – Pages
"The largest share in the healthcare simulation market, based on product & service, was attributed to the medical simulation anatomical models' segment."
The medical simulation anatomical models segment holds the largest market share in the healthcare simulation market. The growth of this segment is propelled by factors such as the rising demand for primary care services and the shortage of healthcare professionals. The hands-on experience with anatomical models enhances skills, fosters confidence, and improves overall patient outcomes. As the demand for effective and safe medical training continues to grow, healthcare simulation anatomical models stand out as indispensable tools, contributing significantly to the dominance of this segment in the healthcare simulation market.
"In 2022, the laparoscopic surgical simulators segment demonstrated the most significant growth in the healthcare simulation market based on type."
The laparoscopic surgical simulators segment is expected to experience the highest growth in the healthcare simulation market. The key drivers for this growth include the widespread adoption of simulation techniques in laparoscopy and advancements in technology within this segment. These simulators replicate the challenges and intricacies of laparoscopic procedures, allowing surgeons to practice and refine their techniques in a risk-free and controlled environment.
"North America accounted for the largest share of the healthcare simulation market in 2022."
In 2022, North America held the largest share in the healthcare simulation market, with Europe and Asia Pacific following. The significant presence of North America in the global market can be attributed to factors such as accessibility to technologies, well-established distribution channels, and a growing number of healthcare professionals seeking hands-on patient training.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1156
Healthcare Simulation Market Dynamics:
DRIVERS
- Limited access to patients during medical training
- Rising technological advancements in medical education
- Growing demand for minimally invasive treatments
- Increasing focus on patient safety
- Growing preference for virtual interaction
RESTRAINTS
- Limited availability of funds
- Poorly designed medical simulators
OPPORTUNITIES
- Shortage of healthcare personnel
- Growing awareness about simulation training in emerging economies
CHALLENGES
- High cost of simulators
- Operational challenges
Key Market Players of Healthcare Simulation Industry:
The key players functioning in the healthcare simulation market include CAE (Canada), Laerdal Medical (Norway), Simulab Corporation (US), Simulaids (US), Limbs & Things (UK), Kyoto Kagaku (Japan), Mentice AB (Sweden), Gaumard Scientific Co. (US), Operative Experience Inc. (US), Cardionics Inc. (US) (a subsidiary of 3B Scientific), VirtaMed AG (Switzerland), SYNBONE AG (Switzerland), IngMar Medical (US), Medical-X (Netherlands), KaVo Dental GmbH (Germany), Altay Scientific (Italy), Simendo B.V. (Netherlands) VRMagic Holding AG (Germany), Symgery (Canada), HRV Simulation (France), Synaptive Medical (Canada), Inovus Medical (UK), TruCorp Ltd. (Ireland), and Surgical Science Sweden AG (Sweden).
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1156
Healthcare Simulation Market - Key Benefits of Buying the Report:
This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers: (Limited access to patients during medical training, Rising technological advancements in medical education), restraints (Increasing focus on patient safety, Growing preference for virtual interaction), opportunities (Growing awareness about simulation training in emerging economies), and challenges (High cost of simulators, Operational challenges) influencing the growth of the healthcare simulation market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the healthcare simulation market.
- Market Development: Comprehensive information on the lucrative emerging markets, products & services, end-users, and regions.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare simulation market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare simulation market like CAE (Canada), Laerdal Medical (Norway), Simulab Corporation (US), Simulaids (US), Limbs & Things (UK).
Related Links:
https://www.marketsandmarkets.com/PressReleases/healthcare-medical-simulation.asp